PCSK9 inhibitors in the current management of atherosclerosis
Arch. cardiol. Méx; 87 (1), 2017
Abstract: The history of proprotein convertase subtilisin/kexin type 9 (PCSK9) in medical science is fascinating and the evolution of knowledge of its function has resulted in new medications of major importance for the cardiovascular (CV) patient. PCSK9 functions as a negative control or feedback for th...